Anti-Human CD74 (CPTC-CD74-1) – Purified No Carrier Protein

CD74 Synthetic Peptide (Cam) (QEEVSHIPAVHPGSFRPK)

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0130A-1G3-H4/K1 activity is directed against human CD74 peptide sequence CQEEVSHIPAVHPGSFRPK.

CPTC-CD74-1

CD74 is a transmembrane protein with proinflammatory and immune system functions¹. CD74 is the cognate receptor for the proinflammatory cytokine MIF (macrophage migration inhibitory factor), which modifies the actions of transcription factors and enzymes and also induces inflammation when secreted. MIF binds to the extracellular domain presented by CD74 to produce context- and cell-type-specific immune responses. Additionally, the intracellular domain of CD74, when cleaved, acts as a chaperone for the MHC class II complex or can enter the nucleus to activate transcription. CD74 regulates transcription in healthy B cells and plays a role in cancer progression by encouraging cell proliferation, inhibiting cell death, and via involvement in intercellular communication between regulatory T cells and fibroblasts, epithelial cells, and B cells in the tumor environment. CD74 is also involved in the etiology of autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and autoimmune-associated kidney disease. CD74 is a target of immunotherapy research².

EB0130A-1G3-H4/K1 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human CD74 that is carbamidomethylated at the cysteine, C[cam]QEEVSHIPAVHPGSFRPK³. EB0130A-1G3-H4/K1 detects CD74 by immunohistochemistry and by Western blotting as a recombinant protein or in cell lysates of Jurkat and MCF7 cell lines⁴. EB0130A-1G3-H4/K1 does not detect CD74 by immunofluorescence or reverse phase protein array.

CD74 is widely expressed in human immune cells, including B cells, monocytes, activated T cell subsets, and macrophages. CD74 is also expressed by dendritic, Langerhans, stromal, epithelial, and endothelial cells.

Cytokine MIF, MHC class II alpha/beta heterodimers, CTSL, CD44

1 Fey RM, Nichols RA, Tran TT, et al. Cancers (Basel). 16(9):1773. 2024.
2 Zhao S, Molina A, Yu A, et al. J Pathol Clin Res. 5(1):12-24. 2019.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-CD74-1